Create Free Account

By creating account you will get access to hot stocks & personalised emails

Integral Diagnostics Ltd

Healthcare AU IDX

3.03AUD
-0.1(3.19%)

Last update at 2024-11-13T05:10:00Z

Day Range

3.013.12
LowHigh

52 Week Range

1.603.20
LowHigh

Fundamentals

  • Previous Close 3.13
  • Market Cap715.92M
  • Volume567047
  • P/E Ratio-
  • Dividend Yield1.93%
  • EBITDA71.55M
  • Revenue TTM469.70M
  • Revenue Per Share TTM2.01
  • Gross Profit TTM 143.76M
  • Diluted EPS TTM-0.26

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 30.63M 22.56M 45.22M 35.26M 30.62M
Minority interest - - - - -
Net income 25.04M 14.60M 31.27M 23.03M 23.03M
Selling general administrative 285.58M 227.00M 207.56M 161.20M 146.12M
Selling and marketing expenses - - - - -
Gross profit 419.06M 339.52M 331.79M 261.60M 220.56M
Reconciled depreciation 43.49M 36.70M 34.91M 25.68M 13.51M
Ebit 49.00M 33.04M 54.13M 43.82M 36.81M
Ebitda 92.48M 69.74M 89.04M 69.50M 50.32M
Depreciation and amortization 43.49M 36.70M 34.91M 25.68M 13.51M
Non operating income net other - - - - -
Operating income 39.83M 38.62M 49.37M 38.43M 36.81M
Other operating expenses 201.74M 149.74M 146.66M 120.66M 194.52M
Interest expense 18.36M 10.48M 8.91M 8.56M 6.19M
Tax provision 5.59M 7.96M 13.95M 12.23M 9.63M
Interest income 18.20M 0.04M 0.09M 7.87M 4.46M
Net interest income -17.94200M -10.44400M -8.82100M -8.55900M -5.92200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.59M 7.96M 13.95M 12.23M 9.63M
Total revenue 440.10M 358.74M 348.81M 274.08M 230.99M
Total operating expenses 379.92M 303.09M 277.61M 214.42M 184.09M
Cost of revenue 21.04M 19.22M 17.02M 12.48M 10.43M
Total other income expense net 9.44M -3.42700M -0.13400M -3.62800M -6.19400M
Discontinued operations - - - - -
Net income from continuing ops 25.04M 14.60M 31.27M 23.03M 20.98M
Net income applicable to common shares 25.04M 14.60M 31.27M 23.03M 20.98M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 744.28M 839.01M 783.01M 654.90M 580.47M
Intangible assets - 30.30M 28.02M 28.94M 27.25M
Earning assets - - - - -
Other current assets 3.56M 2.47M 1.70M 2.25M 4.43M
Total liab 442.57M 465.96M 435.77M 400.16M 352.13M
Total stockholder equity 301.71M 373.05M 347.24M 254.74M 228.33M
Deferred long term liab - - - - -
Other current liab 59.34M 7.48M 16.38M 15.86M 6.94M
Common stock 335.00M 333.28M 322.54M 219.22M 207.44M
Capital stock - 333.28M 322.54M 219.22M 207.44M
Retained earnings -24.96500M 49.56M 37.16M 44.40M 31.69M
Other liab - 34.89M 31.99M 30.88M 27.28M
Good will 373.34M 444.48M 352.46M 315.79M 273.60M
Other assets 0.00000M 19.03M 17.25M 16.34M 13.61M
Cash 42.44M 33.85M 123.19M 62.20M 57.97M
Cash and equivalents - - - - -
Total current liabilities 87.15M 82.67M 80.00M 77.90M 69.80M
Current deferred revenue 1.46M 48.11M 37.72M 40.31M 35.52M
Net debt 315.36M 331.22M 217.80M 246.15M 219.88M
Short term debt 16.17M 16.67M 17.21M 16.97M 22.79M
Short long term debt - 2.45M 5.47M 6.54M 13.18M
Short long term debt total 357.80M 365.08M 340.99M 308.35M 277.85M
Other stockholder equity - -382.83600M -359.69900M -263.62200M -239.13000M
Property plant equipment - 282.46M 231.13M 211.49M 189.58M
Total current assets 74.82M 62.74M 153.98M 82.25M 76.43M
Long term investments - 0.01M 0.16M 0.10M -
Net tangible assets - -101.72400M -33.24300M -89.99000M -72.52400M
Short term investments - 0.38M 0.38M 0.34M 0.40M
Net receivables 27.18M 21.69M 19.41M 14.26M 10.38M
Long term debt - 221.14M 217.58M 192.19M 157.00M
Inventory 1.65M 1.85M 1.26M 0.91M 1.00M
Accounts payable 10.18M 10.41M 8.69M 4.75M 4.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8.32900M -9.78800M -12.45500M -8.88300M -10.80000M
Additional paid in capital - - - - -
Common stock total equity - - - - 207.44M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 25.73M - - - -496.84700M
Deferred long term asset charges - - - - -
Non current assets total 669.46M 776.27M 629.03M 572.65M 504.04M
Capital lease obligations - 141.48M 117.94M 109.63M 96.11M
Long term debt total - 348.41M 323.78M 291.38M 255.06M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -128.95800M -55.69300M -56.66300M -93.53300M -94.97200M
Change to liabilities 1.40M -0.21300M -1.13700M 2.13M 0.34M
Total cashflows from investing activities -128.95800M -55.69300M -56.66300M -93.53300M -94.97200M
Net borrowings -21.41200M 13.04M 8.40M 23.45M 74.03M
Total cash from financing activities -31.84900M 81.13M -7.83400M 75.40M 61.53M
Change to operating activities 5.55M 0.70M 6.57M -1.12200M 1.25M
Net income 25.04M 14.60M 31.27M 23.03M 20.98M
Change in cash -89.33800M 60.99M 4.24M 37.00M 0.12M
Begin period cash flow 123.19M 62.20M 57.97M 20.97M 20.84M
End period cash flow 33.85M 123.19M 62.20M 57.97M 20.97M
Total cash from operating activities 71.42M 37.10M 69.57M 54.25M 32.68M
Issuance of capital stock 2.20M 91.83M 1.79M 73.48M 1.58M
Depreciation 43.49M 36.70M 34.91M 25.68M 13.51M
Other cashflows from investing activities -84.96300M -27.92300M -36.40400M -67.65700M -76.30300M
Dividends paid -12.64000M -20.86300M -17.88600M -18.02900M 14.03M
Change to inventory - - - - -
Change to account receivables -0.35200M -3.43600M -2.91800M -1.71100M -1.99000M
Sale purchase of stock 43.05M 114.15M -0.13900M -3.50900M 131.06M
Other cashflows from financing activities -19.25200M -14.15500M 25.18M 26.11M -0.05200M
Change to netincome -9.44700M -2.46000M 1.25M 2.59M -1.41700M
Capital expenditures 43.99M 27.77M 20.27M 25.88M 18.67M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.35200M -3.43600M -2.91800M -1.71100M -53.22600M
Stock based compensation 2.54M -1.20843M 2.08M 1.34M -
Other non cash items 2.89M -14.20200M 3.39M 5.54M -34.49200M
Free cash flow 27.42M 9.33M 49.30M 28.37M 14.01M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IDX
Integral Diagnostics Ltd		 -0.1 3.19% 3.03 - 20.96 1.52 2.33 2.17 151.08
SHL
Sonic Healthcare Ltd		 -0.23 0.86% 26.46 25.36 22.32 1.45 1.65 1.90 10.21
HLS
Healius Ltd		 -0.015 0.95% 1.56 - 163.93 0.65 1.09 1.53 10.14
ACL
Australian Clinical Labs Ltd		 -0.01 0.28% 3.58 30.50 12.24 1.06 4.17 1.48 6.03
MVF
Monash IVF Group Ltd		 -0.015 1.29% 1.15 - 14.99 1.80 1.91 2.30 54.34

Reports Covered

Stock Research & News

View All

Profile

Integral Diagnostics Limited, a healthcare services company, engages in the provision of diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides positron emission tomography, magnetic resonance imaging, and other radiology services. The company was founded in 1967 and is headquartered in Melbourne, Australia.

Integral Diagnostics Ltd

45 William Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Ian Kadish M.B.A., MBBCh, MBA CEO, MD & Director 1963
Mr. Craig White Chief Financial Officer NA
Mr. Paul McCrow Chief Operating Officer NA
Dr. Jacqueline Milne MBBS Exec. Director NA
Dr. Nazar Bokani M.D. Non-Independent Exec. Director NA
Mr. Julian Gully Chief Information Officer NA
Ms. Mica Duncalfe Chief People Officer NA
Dr. Lisa Sorger MBBS Chief Medical Officer NA
Ms. Kirsty Lally B.Com., C.A. Company Sec. NA
Dr. Ian Kadish M.B.A., MBBCh CEO, MD & Director 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.